Exelixis, Inc. (EXEL) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Alameda, CA, United States. El CEO actual es Michael Morrissey.
EXEL tiene fecha de IPO 2000-04-17, 1,147 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $12.3B.
Exelixis, Inc. is an oncology-focused biotechnology company engaged in the discovery, development, and commercialization of cancer treatments. The company's marketed products include CABOMETYX for advanced renal cell carcinoma, COMETRIQ for medullary thyroid cancer, COTELLIC for advanced melanoma, and MINNEBRO for hypertension in Japan. Exelixis maintains an active pipeline of investigational therapies, including XL092, XB002, and XL102, which target various cancer mechanisms through tyrosine kinase inhibition and other novel pathways. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Ipsen, Takeda, Roche, and Bristol-Myers Squibb to advance its research and development efforts. Headquartered in Alameda, California, Exelixis was founded in 1994 and operates globally in the oncology market.
